SML2369
Tipelukast
≥98% (HPLC)
别名:
4-[6-Acetyl-3-[3-[(4-acetyl-3-hydroxy-2-propylphenyl)thio]propoxy]-2-propylphenoxy]butanoic acid, KCA-757, MN-001
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C29H38O7S
化学文摘社编号:
分子量:
530.67
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
InChI
1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)
SMILES string
CCCC1=C(SCCCOC2=C(CCC)C(OCCCC(O)=O)=C(C(C)=O)C=C2)C=CC(C(C)=O)=C1O
InChI key
KPWYNAGOBXLMSE-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Antifibrotic and anti-inflammatory Leukotriene D4 (LTD4) receptor antagonist and inhibitor of 5-lipoxygenase (5-LO) and phosphodiesterases PDE3 and PDE4.
Tipelukast is a Leukotriene D4 (LTD4) receptor antagonist and an inhibitor of 5-lipoxygenase (5-LO) and also phosphodiesterases PDE3 and PDE4. It has been found to have antifibrotic and anti-inflammatory activity. Tipelukast has been investigated as a possible treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Nonalcoholic steatohepatitis (NASH) drugs market.
Sorcha Cassidy et al.
Nature reviews. Drug discovery, 15(11), 745-746 (2016-11-04)
Yoshio Sumida et al.
Journal of gastroenterology, 53(3), 362-376 (2017-12-17)
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持